查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1728083

偏頭痛治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療學、給藥途徑、配銷通路、地區和競爭細分，2020 年至 2030 年預測

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球偏頭痛治療市場價值為 38.9 億美元，預計到 2030 年將達到 50.1 億美元，預測期內複合年成長率為 4.31%。由於偏頭痛發病率的上升、患者意識的增強以及藥物開發的快速進步，該市場正在穩步擴大。偏頭痛是一種慢性神經系統疾病，影響著全球大量人口，因此對有效的治療方案的需求十分強烈。在降鈣素基因相關胜肽 (CGRP) 抑制劑和 gepants 等持續創新的支持下，治療正在朝著更有針對性和個性化的方向發生顯著轉變，這些創新已顯示出良好的臨床效果。人們對偏頭痛對公共健康和經濟影響的認知不斷提高，也推動了公共和私營部門對研發的投資。隨著製藥公司專注於推出下一代藥物和生物製劑，市場繼續朝著更有效和個人化的治療策略發展。這些創新，加上人們意識的提高和醫療保健管道的改善，預計將支持市場持續成長。

市場概覽
預測期 2026-2030
2024年市場規模 38.9億美元
2030年市場規模 50.1億美元
2025-2030 年複合年成長率 4.31%
成長最快的領域 止痛藥
最大的市場 北美洲

關鍵市場促進因素

偏頭痛盛行率高

主要市場挑戰

藥物開發的複雜性

主要市場趨勢

精準醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：臨床試驗分析

第5章：顧客之聲

第6章：全球偏頭痛治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療學分類 {止痛藥（鎮痛藥、曲坦類藥物、麥角生物鹼等）及預防藥物（降血壓藥、抗驚厥藥、降鈣素基因相關胜肽 (CGRP) 拮抗劑、其他預防療法）}
    • 依給藥途徑（口服及鼻腔給藥、注射劑）
    • 按配銷通路（零售藥房、醫院藥房、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第7章：北美偏頭痛治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲偏頭痛治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第9章：亞太偏頭痛治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 10 章：南美洲偏頭痛治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲偏頭痛治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 近期發展
  • 併購

第 14 章：全球偏頭痛治療市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代治療類型的威脅

第 16 章：競爭格局

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16304

The Global Migraine Therapeutics Market was valued at USD 3.89 Billion in 2024 and is projected to reach USD 5.01 Billion by 2030, growing at a CAGR of 4.31% during the forecast period. This market is expanding steadily due to the rising incidence of migraine, growing patient awareness, and rapid advancements in drug development. Migraine, a chronic neurological condition, affects a significant global population, leading to strong demand for effective treatment options. A notable shift is occurring toward more targeted and individualized therapies, supported by ongoing innovations such as calcitonin gene-related peptide (CGRP) inhibitors and gepants, which are demonstrating promising clinical outcomes. Increased recognition of migraine's public health and economic impacts has also driven investment in R&D by both public and private sectors. With pharmaceutical companies focusing on introducing next-generation drugs and biologics, the market continues to evolve toward more effective and personalized treatment strategies. These innovations, along with greater awareness and improved access to healthcare, are expected to support sustained market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.89 Billion
Market Size 2030USD 5.01 Billion
CAGR 2025-20304.31%
Fastest Growing SegmentPain-Relieving Medications
Largest MarketNorth America

Key Market Drivers

High Prevalence of Migraine

The widespread occurrence of migraine is a key driver fueling the growth of the Migraine Therapeutics Market. Migraine affects individuals of all ages, genders, and demographics, making it a pervasive public health issue. The condition is a leading cause of disability and contributes to significant losses in productivity, impacting both individuals and economies. As per a March 2024 WHO report, around 40% of the global population-approximately 3.1 billion people-suffered from migraines and other headache disorders as of 2021. The condition shows a higher prevalence among women, likely due to hormonal factors. Migraine ranks among the top three neurological disorders from childhood through late adulthood. This widespread burden has led to increased attention from healthcare stakeholders, driving awareness, diagnosis, and treatment. The rising recognition of migraine's impact on quality of life has also encouraged the development and uptake of more effective therapies, including CGRP inhibitors and gepants, further expanding the market.

Key Market Challenges

Drug Development Complexity

Developing effective migraine therapeutics presents significant challenges due to the complex nature of the condition. Migraine manifests with diverse symptoms and triggers, requiring a deep understanding of its neurological basis for effective drug design. Identifying precise molecular targets is difficult, as the underlying mechanisms of migraine are still not fully understood. The clinical trial process for migraine treatments can be lengthy and costly, involving large patient populations and extended follow-up periods. Subjective symptom reporting and placebo responses add further complexity. Regulatory agencies such as the FDA require comprehensive evidence of safety and efficacy, necessitating rigorous testing and data collection. In addition, evolving clinical trial endpoints demand constant adaptation from researchers and sponsors. These challenges, combined with high development costs, can delay innovation and restrict market entry, particularly for smaller firms.

Key Market Trends

Precision Medicine

Precision medicine is emerging as a transformative trend in the Migraine Therapeutics Market, offering more effective and individualized treatment strategies. By utilizing genetic, molecular, and clinical data, precision medicine allows for the customization of therapies based on a patient's unique migraine profile. Advances in genetic testing and biomarker analysis enable pharmaceutical developers and healthcare providers to better identify subgroups of patients who are most likely to benefit from specific treatments. This targeted approach improves treatment outcomes, reduces side effects, and enhances patient satisfaction. For pharmaceutical companies, precision medicine increases the efficiency of drug development and can lead to faster regulatory approvals. It also offers the potential for higher market differentiation and pricing power. As demand grows for more personalized healthcare solutions, the integration of precision medicine into migraine treatment protocols is expected to expand significantly, reshaping the market landscape and improving therapeutic success rates.

Key Market Players

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

Report Scope:

In this report, the Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Migraine Therapeutics Market, Therapeutics:

  • Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others)
  • Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)

Migraine Therapeutics Market, Route of Administration:

  • Oral & Nasal
  • Injectables

Migraine Therapeutics Market, Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Migraine Therapeutics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Migraine Therapeutics Market.

Available Customizations:

Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Therapeutic Area
  • 4.7. Breakdown of Pipeline. By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global Migraine Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
    • 6.2.2. By Route of Administration (Oral & Nasal, Injectables)
    • 6.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Migraine Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Migraine Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Migraine Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Migraine Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. Europe Migraine Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Migraine Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. United Kingdom Migraine Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Italy Migraine Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. France Migraine Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Migraine Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Migraine Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Migraine Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Migraine Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Migraine Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Migraine Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapeutics
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Migraine Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapeutics
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. South America Migraine Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Migraine Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Migraine Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Migraine Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Migraine Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapeutics
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Migraine Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapeutics
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Migraine Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapeutics
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Migraine Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapeutics
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions

14. Global Migraine Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Treatment Types

16. Competitive Landscape

  • 16.1. Amgen Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Teva Pharmaceutical Industries Limited
  • 16.3. GlaxoSmithKline plc
  • 16.4. Eli Lilly and Company
  • 16.5. Bausch Health Companies Inc.
  • 16.6. Novartis AG
  • 16.7. AbbVie Inc.
  • 16.8. Lundbeck Inc
  • 16.9. Dr. Reddy's Laboratories Limited
  • 16.10. Impel Pharmaceuticals Inc

17. Strategic Recommendations

18. About Us & Disclaimer